Quick Answer
Regen BioPharma Inc reported Research And Development Expense of $11.7 thousand for the year ending 2025.
- Regen BioPharma Inc showed a decrease of -92.4% in Research And Development Expense from 2024 to 2025.
- This data is from Regen BioPharma Inc's annual report (Form 10-K), filed with the SEC on December 30, 2025.
- XBRL data for this metric is available from 2013 to 2025 (13 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q2 2013: $3.0 thousand | Q4 2013: $5.8 thousand | Q1 2014: $8.0 thousand | Q2 2014: $0.00 | Q4 2014: $2.2 thousand | Q1 2015: $23.0 thousand | Q2 2015: $68.1 thousand | Q4 2015: $105.3 thousand | Q1 2016: $172.1 thousand | Q2 2016: $208.3 thousand | Q4 2016: $42.7 thousand | Q1 2017: $284.7 thousand | Q2 2017: $374.5 thousand | Q4 2017: $548.1 thousand | Q1 2018: $71.9 thousand | Q2 2018: $10.4 thousand | Q4 2018: $6.6 thousand | Q1 2019: $1.3 thousand | Q2 2019: $15.3 thousand | Q4 2019: $7.5 thousand | Q1 2020: $2.8 thousand | Q2 2020: $12.00 | Q4 2020: $1.1 thousand | Q1 2021: $512.00 | Q2 2021: $14.3 thousand | Q4 2021: $35.4 thousand | Q1 2022: $27.4 thousand | Q2 2022: $31.1 thousand | Q4 2022: $95.5 thousand | Q1 2023: $36.4 thousand | Q2 2023: $45.0 thousand | Q4 2023: $47.5 thousand | Q1 2024: $40.1 thousand | Q2 2024: $32.5 thousand | Q4 2024: $0.00 | Q4 2025: $210.0 thousand.
- Over the full 13 years of available data (2013 to 2025), Regen BioPharma Inc's Research And Development Expense has grown by 39.7%.
- Historical annual values: Fiscal year 2025: $11.7 thousand | Fiscal year 2024: $153.7 thousand | Fiscal year 2023: $212.3 thousand | Fiscal year 2022: $158.1 thousand | Fiscal year 2021: $36.7 thousand | Fiscal year 2020: $13.3 thousand | Fiscal year 2019: $45.6 thousand | Fiscal year 2018: $374.4 thousand | Fiscal year 2017: $1.15 million | Fiscal year 2016: $671.1 thousand | Fiscal year 2015: $282.3 thousand | Fiscal year 2014: $23.9 thousand | Fiscal year 2013: $8.4 thousand.
- Data sourced from SEC EDGAR public filings as of August 6, 2026.
Last verified: